Consensus Grows:
"Drug Pricing System Reform Must Foster Industry Growth and Development"

In response to the government’s upcoming announcement on drug pricing system reforms, the “Emergency Committee for Drug Pricing System Reform for Industrial Development,” comprising stakeholders from the entire pharmaceutical and bio-pharma industry, will be launched.

Seoul Seocho-gu Korea Pharmaceutical and Bio-Pharma Manufacturers Association building. Korea Pharmaceutical and Bio-Pharma Manufacturers Association

Seoul Seocho-gu Korea Pharmaceutical and Bio-Pharma Manufacturers Association building. Korea Pharmaceutical and Bio-Pharma Manufacturers Association

View original image

The Korea Pharmaceutical and Bio-Pharma Manufacturers Association held an emergency board meeting at the association’s Future Hall in Seocho-gu, Seoul, on the 24th and resolved to form the emergency committee to coordinate a joint response from the domestic pharmaceutical and bio-pharma industry regarding the drug pricing system reform.


During the meeting, participants shared the view that the drug pricing system reform plan, which the Ministry of Health and Welfare is expected to release later this week, could undermine the development of Korea’s pharmaceutical and bio-pharma industry and run counter to the government’s policy direction of establishing Korea as one of the world’s top five pharmaceutical and bio-pharma powerhouses.


The emergency committee will include the Korea Pharmaceutical and Bio-Pharma Manufacturers Association, the Korea Biomedicine Industry Association, the Korea Pharmaceutical Traders Association, the Korea Drug Research Association, and the Korea Pharmaceutical Cooperative Association. The committee will operate a rapid response system centered on three subcommittees: the Planning and Policy Committee, the External Cooperation Committee, and the Public Communication Committee.


At the meeting, participants discussed the progress made so far and the future schedule regarding the government’s proposed drug pricing system reform, as well as the potential impact on the industry if the reforms are implemented. Participants agreed that the reform plan should not undermine the innovation momentum of companies preparing to elevate Korea to a global pharmaceutical powerhouse, as evidenced by the global expansion of domestically developed new drugs, Korea’s status as the world’s third-largest holder of new drug pipelines, and record-breaking achievements in new drug technology transfer.


Accordingly, the emergency committee will actively raise concerns about the potential weakening of research and development capabilities and disruptions to R&D investment plans that the industry may face. Once the government announces a specific reform plan, the committee will present rational opinions based on a comprehensive impact analysis.



In addition, the committee will recommend that the government’s drug pricing reform plan should not focus solely on reducing health insurance expenditures, but should also help strengthen the industry’s competitiveness by ensuring appropriate compensation for active R&D investment by pharmaceutical and bio-pharma companies and by building an ecosystem that recognizes the value of innovation.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing